Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd (600671) - Total Assets
Based on the latest financial reports, Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd (600671) holds total assets worth CN¥429.73 Million CNY (≈ $62.88 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Hangzhou TianMuShan Pharmaceutical Enter (600671) shareholders funds for net asset value and shareholders' equity analysis.
Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd - Total Assets Trend (1993–2024)
This chart illustrates how Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd's total assets have evolved over time, based on quarterly financial data.
Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd's total assets of CN¥429.73 Million consist of 50.5% current assets and 49.6% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 14.9% |
| Accounts Receivable | CN¥100.54 Million | 22.8% |
| Inventory | CN¥52.32 Million | 11.9% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥5.09 Million | 1.2% |
| Goodwill | CN¥1.61 Million | 0.4% |
Asset Composition Trend (1993–2024)
This chart illustrates how Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Hangzhou TianMuShan Pharmaceutical Enter worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd's current assets represent 50.5% of total assets in 2024, a decrease from 60.7% in 1993.
- Cash Position: Cash and equivalents constituted 14.9% of total assets in 2024, up from 6.3% in 1993.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 4.0% in 1993.
- Asset Diversification: The largest asset category is accounts receivable at 22.8% of total assets.
Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd Competitors by Total Assets
Key competitors of Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Novartis AG
MX:NVSN
|
Mexico | MX$110.95 Billion |
|
Novo Nordisk A/S
CO:NOVO-B
|
Denmark | Dkr542.90 Billion |
|
Novartis AG
SW:NOVN
|
Switzerland | CHF115.49 Billion |
|
Pfizer Inc
SA:PFIZ34
|
Brazil | R$208.73 Billion |
|
Firebrick Pharma Ltd
AU:FRE
|
Australia | AU$1.83 Million |
|
Eli Lilly and Company
SA:LILY34
|
Brazil | R$112.48 Billion |
|
Dimed S.A. Distribuidora de Medicamentos
SA:PNVL3
|
Brazil | R$3.83 Billion |
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SHG:600436
|
China | CN¥17.48 Billion |
Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.81 | 0.65 | 0.89 |
| Quick Ratio | 0.66 | 0.45 | 0.62 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥-52.79 Million | CN¥-80.01 Million | CN¥-28.96 Million |
Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd - Advanced Valuation Insights
This section examines the relationship between Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 38.46 |
| Latest Market Cap to Assets Ratio | 0.80 |
| Asset Growth Rate (YoY) | 27.5% |
| Total Assets | CN¥441.46 Million |
| Market Capitalization | $351.06 Million USD |
Valuation Analysis
Below Book Valuation: The market values Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd's assets below their book value (0.80x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd's assets grew by 27.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd (1993–2024)
The table below shows the annual total assets of Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd from 1993 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥441.46 Million ≈ $64.60 Million |
+27.48% |
| 2023-12-31 | CN¥346.29 Million ≈ $50.67 Million |
+15.49% |
| 2022-12-31 | CN¥299.84 Million ≈ $43.88 Million |
-25.53% |
| 2021-12-31 | CN¥402.65 Million ≈ $58.92 Million |
-9.01% |
| 2020-12-31 | CN¥442.51 Million ≈ $64.75 Million |
-16.02% |
| 2019-12-31 | CN¥526.93 Million ≈ $77.11 Million |
+9.64% |
| 2018-12-31 | CN¥480.62 Million ≈ $70.33 Million |
+6.70% |
| 2017-12-31 | CN¥450.44 Million ≈ $65.91 Million |
+47.11% |
| 2016-12-31 | CN¥306.19 Million ≈ $44.81 Million |
+9.21% |
| 2015-12-31 | CN¥280.38 Million ≈ $41.03 Million |
-1.84% |
| 2014-12-31 | CN¥285.64 Million ≈ $41.80 Million |
-12.18% |
| 2013-12-31 | CN¥325.27 Million ≈ $47.60 Million |
+9.92% |
| 2012-12-31 | CN¥295.92 Million ≈ $43.30 Million |
-17.30% |
| 2011-12-31 | CN¥357.84 Million ≈ $52.36 Million |
+11.90% |
| 2010-12-31 | CN¥319.79 Million ≈ $46.80 Million |
-2.58% |
| 2009-12-31 | CN¥328.27 Million ≈ $48.04 Million |
-11.06% |
| 2008-12-31 | CN¥369.08 Million ≈ $54.01 Million |
-10.87% |
| 2007-12-31 | CN¥414.09 Million ≈ $60.59 Million |
+17.48% |
| 2006-12-31 | CN¥352.47 Million ≈ $51.58 Million |
-5.43% |
| 2005-12-31 | CN¥372.71 Million ≈ $54.54 Million |
+4.15% |
| 2004-12-31 | CN¥357.85 Million ≈ $52.37 Million |
+3.27% |
| 2003-12-31 | CN¥346.52 Million ≈ $50.71 Million |
-7.23% |
| 2002-12-31 | CN¥373.53 Million ≈ $54.66 Million |
-8.62% |
| 2001-12-31 | CN¥408.75 Million ≈ $59.81 Million |
+0.71% |
| 2000-12-31 | CN¥405.88 Million ≈ $59.39 Million |
+19.45% |
| 1999-12-31 | CN¥339.78 Million ≈ $49.72 Million |
+5.19% |
| 1998-12-31 | CN¥323.01 Million ≈ $47.27 Million |
+9.24% |
| 1997-12-31 | CN¥295.69 Million ≈ $43.27 Million |
+14.02% |
| 1996-12-31 | CN¥259.33 Million ≈ $37.95 Million |
-1.40% |
| 1995-12-31 | CN¥263.02 Million ≈ $38.49 Million |
+36.90% |
| 1994-12-31 | CN¥192.12 Million ≈ $28.11 Million |
+69.27% |
| 1993-12-31 | CN¥113.50 Million ≈ $16.61 Million |
-- |
About Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd, together with its subsidiaries, engages in the pharmaceutical manufacturing and drug distribution businesses in China. The company produces and sells medicines and related health care products, including tablets, granules, pills, mixtures, oral liquids, syrups, eye drops, pills, soft capsules, tablets, hard capsules, and other health foods. I… Read more